Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC
January 21st 2023The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.
Clinical Benefit for ARV-471 Continues to Impress in Expansion Cohort in ER+/HER2– Breast Cancer
December 8th 2022Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.
BI 1810631 Shows Early Antitumor Activity in NSCLC
December 4th 2022Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30th 2022As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.